{
  "docId": "019de074-15c9-703f-ba69-83bd63385db9",
  "docSlug": "61dc585c6c50f6919636d426c025da60",
  "documentTitle": "AstraZeneca | Investor Event Presentation Deck | 42 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 7,
  "pageCount": 42,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "The slide uses a four-column layout to segment strategic focus areas (HER2-high, HR+, gBRCA, TNBC).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-15c9-703f-ba69-83bd63385db9/7",
  "deckHref": "/decks/019de074-15c9-703f-ba69-83bd63385db9",
  "deckJsonHref": "/decks/019de074-15c9-703f-ba69-83bd63385db9.json",
  "deckAnchorHref": "/decks/019de074-15c9-703f-ba69-83bd63385db9#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.03,
        "y": 0.95
      },
      "kind": "disclaimer",
      "text": "SABCS = San Antonio Breast Cancer Symposium; HER2 = human epidermal growth factor receptor 2; HR+ = hormone receptor positive; ET = endocrine therapy; ER = oestrogen receptor; ADC = antibody drug conjugate; gBRCA = breast cancer gene; TiP = trials in progress poster; IO = immuno-oncology; TNBC = triple negative breast cancer.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1cdc6fe3-c110-4dc1-8c0c-98164647e558",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.22,
        "x": 0.03,
        "y": 0.27
      },
      "kind": "list",
      "text": "Setting new standards of care in HER2-high mBC; Enhertu as foundational therapy; DESTINY-Breast03; DESTINY-Breast02",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "409bbab2-c407-40f9-a615-356540ea0ef8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.22,
        "x": 0.51,
        "y": 0.27
      },
      "kind": "list",
      "text": "Establishing and expanding beyond gBRCA; Reinforcing role of Lynparza (OlympiaN TiP)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "67c171d7-6045-435d-91f5-4c0d813e6c8a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.22,
        "x": 0.75,
        "y": 0.27
      },
      "kind": "list",
      "text": "Redefining the treatment and understanding of TNBC; ADCs with IO (BEGONIA); Dato-DXd monotherapy (TROPION-PanTumor01)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "be2d1c72-b542-4477-b451-6f77edb5253b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.24,
        "x": 0.26,
        "y": 0.27
      },
      "kind": "list",
      "text": "Reshaping the treatment of HR+; camizestrant (SERENA-2); capivasertib (CAPItello-291); Best-in-class ADCs (DESTINY-Breast04, TROPION-PanTumor01)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d70f4b6e-899b-4ee1-b95c-e019bf900eb3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "Key data advances our strategic ambitions in breast cancer",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b4907037-e04f-41b8-89fc-9da02a4ea138",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "AstraZeneca at SABCS 2022",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ef3060de-464a-439d-bca9-9047de8d482b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "market-segmentation",
      "slug": null,
      "matchId": "2f7151e4-1679-4a61-b156-e1d12318ecf4",
      "evidence": "The slide segments the breast cancer market by patient sub-type (HER2-high, HR+, gBRCA, TNBC) to align strategic initiatives.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 9,
      "from": 6,
      "beatId": "22d3e816-46f2-4036-849e-d23ee30b135a",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Complication",
      "beatSlug": "complication",
      "evidence": "Key data and unmet need in breast cancer",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}